Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RYTM | 8-K | bullish | 6/10 | On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive interim clinical data from its Phase 2 trial of s | Jun 15, 2026 |
| JSPR | DEFA14A | neutral | 2/10 | Jasper Therapeutics filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting scheduled for July | Jun 15, 2026 |
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon ac | Jun 15, 2026 |
| PDSB | 8-K | bearish | 7/10 | PDS Biotechnology closed a $6M promissory note financing with Yorkville affiliate YA II PN, Ltd. (10% interest, 12-month | Jun 15, 2026 |
| GWTI | 8-K | neutral | 2/10 | Greenway Technologies entered into a 3-year employment agreement and stock award agreement with CEO Doug Cogan on June 1 | Jun 15, 2026 |
| CXXIF | 6-K | bullish | 7/10 | C21 Investments Inc. announced a definitive arrangement agreement to be acquired by Vireo Growth Inc. in an all-stock tr | Jun 15, 2026 |
| ADTX | 3 | neutral | 2/10 | Bank of America entities filed a Form 3 disclosing beneficial ownership of 57 shares of Aditxt common stock, held indire | Jun 15, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced an exclusive worldwide IP license agreement with Project LightShift for quantum photonic array t | Jun 15, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab filed a 6-K reporting that Orbis Investment Management Limited reduced its stake from 5.0783% to 4.9917% (3,112,4 | Jun 15, 2026 |
| RKDA | 8-K | bearish | 7/10 | Arcadia Biosciences (RKDA) raised approximately $4M in a private placement of pre-funded warrants and investment options | Jun 15, 2026 |
| XNCR | 144 | neutral | 2/10 | Director Alan Bruce Montgomery filed a Form 144 notice of intent to sell 5,064 shares of Xencor Inc (XNCR) with an estim | Jun 15, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab A/S filed its updated Articles of Association via a 6-K on June 15, 2026, reflecting standard corporate governanc | Jun 15, 2026 |
| SLBT | 3 | neutral | 2/10 | Joseph Levinson filed an initial statement of beneficial ownership (Form 3) for SL Science Holding Ltd (SLBT), a Taiwan- | Jun 15, 2026 |
| XNCR | 144 | neutral | 2/10 | Director Richard J. Ranieri filed a Form 144 to sell 5,474 shares of Xencor Inc (XNCR) worth approximately $68,385, acqu | Jun 15, 2026 |
| GSK | 6-K | neutral | 3/10 | GSK filed a routine 6-K disclosing weekly share repurchases under its existing buyback program. The company bought ~1.1M | Jun 15, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem filed a 6-K announcing the election/re-election of members to its Board advisory committees following the new Sh | Jun 15, 2026 |
| INCR | 6-K | mixed | 5/10 | InterCure completed the first tranche of its Botanico acquisition, issuing 2.47M shares (with another 2.47M to follow), | Jun 15, 2026 |
| CNTX | 8-K | bullish | 7/10 | Context Therapeutics announced positive interim Phase 1a data for CTIM-76, a CLDN6 x CD3 T cell engager, in heavily pret | Jun 15, 2026 |
| ENGN | 8-K | bearish | 6/10 | enGene Therapeutics reported Q2 2026 results with a net loss of $0.43/share, beating consensus of -$0.48, but announced | Jun 15, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia reported additional positive Phase 3 HAELO results for lonvo-z (CRISPR gene editing candidate) in hereditary an | Jun 15, 2026 |
| SLBT | 6-K | neutral | 5/10 | SL Science Holding Ltd (SLBT) announced the closing of its business combination with SPAC Horizon Space Acquisition II C | Jun 15, 2026 |
| SNSE | 8-K | bearish | 6/10 | Sensei Biotherapeutics (SNSE) filed an 8-K confirming its name change to Faeth Therapeutics (ticker FTH effective June 1 | Jun 15, 2026 |
| NMRA | 8-K | bearish | 7/10 | Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder fa | Jun 15, 2026 |
| OPK | PRESS-RELEASE | neutral | 3/10 | OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 202 | Jun 15, 2026 |
| SYRE | 8-K | bullish | 7/10 | Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 | Jun 15, 2026 |
| AIM | 8-K | bullish | 5/10 | AIM ImmunoTech received formal notice from NYSE American that it has regained compliance with continued listing standard | Jun 15, 2026 |
| TELO | 8-K | neutral | 3/10 | Telomir Pharmaceuticals announced a peer-reviewed publication of preclinical data for Telomir-Zn in a zebrafish model of | Jun 15, 2026 |
| PDSB | 8-K | neutral | 2/10 | PDS Biotechnology Corp filed an 8-K to announce that its 2026 Annual Meeting of Stockholders is scheduled for August 10, | Jun 15, 2026 |
| MEHA | 8-K | bearish | 7/10 | Functional Brands Inc. received a Nasdaq Staff Delisting Determination because its common stock closed at $0.10 or less | Jun 15, 2026 |
| APTOF | 8-K | bullish | 7/10 | Aptose Biosciences presented updated Phase 1/2 TUSCANY trial data for tuspetinib (TUS) triplet therapy in newly diagnose | Jun 15, 2026 |